BioMarin Appoints Ian T. Clark to Board of Directors Enhancing Leadership Team

BioMarin Welcomes Ian T. Clark to Board of Directors

BioMarin Pharmaceutical Inc. has officially welcomed Ian T. Clark to its Board of Directors effective August 1, 2025. This strategic appointment aims to enrich the company’s leadership with Mr. Clark's vast experience in the biopharmaceutical sector.

Previous Leadership at Genentech

Ian T. Clark is well-known in the industry for his tenure as Chief Executive Officer at Genentech. He led that company from 2010 until his retirement in 2016, during which time Genentech successfully launched an impressive 15 new drugs. His robust background with Genentech includes various senior management roles, further solidifying his reputation as a key figure in the biotech field.

Before his association with Genentech, Mr. Clark garnered 23 years of substantial experience at leading biopharmaceutical companies, such as Novartis International AG, Sanofi S.A., Ivax Pharmaceuticals, and G.D. Searle. His wealth of knowledge from these organizations positions him as a valuable asset to BioMarin, especially as the company continues to innovate in the biopharmaceutical landscape.

A Diverse Board Member

In addition to his role at BioMarin, Mr. Clark serves on the boards of several other companies including Olema Oncology, Takeda Pharmaceutical Company Ltd., and Guardant Health, Inc. He has previously contributed his expertise to Forty Seven Inc., Shire Pharmaceuticals, and Kite Pharma, showing a commitment to advancing the biotech industry.

Mr. Clark is also involved with KKR & Co. Inc., and has provided guidance to the Biotechnology Industry Organization. His deep understanding of the economic landscape is supplemented by his past role on the 12th District Economic Advisory Council of the Federal Reserve.

A Proud Addition to BioMarin

Alexander Hardy, President and CEO of BioMarin, expressed excitement over Ian Clark's appointment: "We are very pleased to welcome Ian to our Board of Directors. He is a respected leader, involved in the development and launch of numerous therapies for patients with unmet needs. His experience over three decades as a biopharmaceutical executive will provide invaluable perspective, ensuring he is an ideal fit for our Board."

In response, Mr. Clark stated that he is delighted to join BioMarin’s Board as the company progresses in developing ground-breaking medicines for genetically defined conditions. He looks forward to contributing to the mission of reaching more patients globally.

About BioMarin

Founded in 1997, BioMarin is headquartered in San Rafael, California. The company is dedicated to transforming genetic discoveries into meaningful medicine, boasting a portfolio of eight approved therapies along with a promising pipeline of clinical and preclinical candidates. BioMarin's approach to drug discovery emphasizes addressing rare and challenging genetic conditions, providing hope to patients and their families around the world.

To learn more about BioMarin and its innovative therapies, visit www.biomarin.com.

Forward-Looking Statements

This announcement contains forward-looking remarks regarding BioMarin Pharmaceutical Inc., emphasizing the expectations surrounding Mr. Ian Clark's appointment and the company’s strategies moving forward. Investors are advised that these statements come with risks and uncertainties that could cause actual outcomes to differ significantly.

BioMarin, as a leading name in the biotechnology sector, is committed to providing updates on its initiatives, ensuring stakeholders are well aware of developments as they unfold.